AIDS
MCID: HMN044
MIFTS: 78

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Cancer diseases, Genetic diseases, Immune diseases, Mental diseases

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 57 37
Aids 57 74 54 3 17
Human Immunodeficiency Virus Type 1, Susceptibility to 57 29 6
Aids, Delayed/rapid Progression to 57 13 6
Hiv/aids 57 42 3
Hiv-1 Viremia, Susceptibility to 57 6
Rapid Progression to Aids from Hiv1 Infection 57
Human Immunodeficiency Virus I Infection 71
Acquired Immunodeficiency Syndrome 71
Hiv1 Infection, Resistance to 57
Hiv Type 1, Susceptibility to 57
Hiv Infection, Resistance to 57
Hiv/aids, Susceptibility to 57
Aids, Rapid Progression to 57
Aids, Slow Progression to 57
Hiv-1, Susceptibility to 57
Hiv-1, Resistance to 57
Aids, Resistance to 57
Hiv1, Resistance to 57
Hiv-Infection/aids 71
Hiv-1 Infection 17
Hiv1 Infection 57
Hiv-1 Viremia 57
Hiv Type 1 57
Hiv-1 57
Hiv1 57

Classifications:



External Ids:

OMIM® 57 609423
UMLS 71 C0001175 C0276500 C0497169

Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus : 42 What is HIV? HIV stands for human immunodeficiency virus. It harms your immune system by destroying a type of white blood cell that helps your body fight infection. This puts you at risk for serious infections and certain cancers. What is AIDS? AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. It happens when the body's immune system is badly damaged because of the virus. Not everyone with HIV develops AIDS. How does HIV spread? HIV can spread in different ways: Through unprotected sex with a person with HIV. This is the most common way that it spreads. By sharing drug needles Through contact with the blood of a person with HIV From mother to baby during pregnancy, childbirth, or breastfeeding Who is at risk for HIV infection? Anyone can get HIV, but certain groups have a higher risk of getting it: People who have another sexually transmitted disease (STD). Having an STD can increase your risk of getting or spreading HIV. People who inject drugs with shared needles • Gay and bisexual men, especially those who are Black/African American or Hispanic/Latino American People who engage in risky sexual behaviors, such as not using condoms What are the symptoms of HIV/AIDS? The first signs of HIV infection may be flu-like symptoms: Fever Chills Rash Night sweats Muscle aches Sore throat Fatigue Swollen lymph nodes Mouth ulcers These symptoms may come and go within two to four weeks. This stage is called acute HIV infection. If the infection is not treated, it becomes chronic HIV infection. Often, there are no symptoms during this stage. If it is not treated, eventually the virus will weaken your body's immune system. Then the infection will progress to AIDS. This is the late stage of HIV infection. With AIDS, your immune system is badly damaged. You can get more and more severe infections. These are known as opportunistic infections (OIs). Some people may not feel sick during the earlier stages of HIV infection. So the only way to know for sure whether you have HIV is to get tested. How do I know if I have HIV? A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. You can also use the CDC Testing Locator to find free testing sites. What are the treatments for HIV/AIDS? There is no cure for HIV infection, but it can be treated with medicines. This is called antiretroviral therapy (ART). ART can make HIV infection a manageable chronic condition. It also reduces the risk of spreading the virus to others. Most people with HIV live long and healthy lives if they get and stay on ART. It's also important to take care of yourself. Making sure that you have the support you need, living a healthy lifestyle, and getting regular medical care can help you enjoy a better quality of life. Can HIV/AIDS be prevented? You can reduce the risk of spreading HIV by Getting tested for HIV Choosing less risky sexual behaviors. This includes limiting the number of sexual partners you have and using condoms every time you have sex. Getting tested and treated for sexually transmitted diseases (STDs) Not injecting drugs Talking to your health care provider about medicines to prevent HIV: PrEP (pre-exposure prophylaxis) is for people who don't already have HIV but are at very high risk of getting it. PrEP is daily medicine that can reduce this risk. PEP (post-exposure prophylaxis) is for people who have possibly been exposed to HIV. It is only for emergency situations. PEP must be started within 72 hours after a possible exposure to HIV. NIH: National Institutes of Health

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as aids, is related to immune deficiency disease and acquired immunodeficiency syndrome, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pyrazinamide and Glycerol have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and brain, and related phenotypes are Decreased viability and Decreased viability

OMIM® : 57 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423) (Updated 05-Mar-2021)

CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

Wikipedia : 74 Human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2219)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 33.9 ITIH4 IL10 IFNG CXCL12 CX3CR1 CD9
2 acquired immunodeficiency syndrome 32.9 ITIH4 IL10 IFNG CD9 CCR5 CCR2
3 human immunodeficiency virus infectious disease 32.5 KIR3DL1 ITIH4 IL10 IFNG CXCL12 CX3CR1
4 stomatitis 32.3 IL10 IFNG BST2
5 viral infectious disease 32.2 TLR3 KIR3DL1 ITIH4 IL10 IFNG CD9
6 syphilis 32.0 HLA-C CD209 CCR5
7 encephalitis 32.0 TLR3 ITIH4 IL10 CD209 CCR5 CCL3
8 pulmonary tuberculosis 31.9 IL10 IFNG CCL3 CCL2
9 hepatitis c 31.9 TLR3 IL10 IFNG CCR5
10 bacterial infectious disease 31.8 TLR3 IL10 IFNG CCL3 CCL2
11 mycobacterium tuberculosis 1 31.8 IL10 IFNG CD209 CCL3
12 aids dementia complex 31.8 ITIH4 CXCL12
13 toxoplasmosis 31.7 IL10 IFNG CCR5 CCL3
14 disease by infectious agent 31.6 ITIH4 IL10 IFNG CD209 CCR5 CCL3
15 cytomegalovirus retinitis 31.6 IL10 IFNG CXCL12 CD9 CCR5 CCR2
16 retinal detachment 31.6 IL10 IFNG CXCL12 CCL2
17 pelvic inflammatory disease 31.6 IFNG CXCL12 CCL2
18 schistosomiasis 31.5 IL10 IFNG CCL3 CCL2
19 leprosy 3 31.5 IL10 IFNG CD209 CCL2
20 demyelinating disease 31.5 IL10 IFNG CCL3 CCL2
21 herpes zoster 31.5 TLR3 IL10 IFNG CCR5
22 allergic disease 31.5 IL4R IFNG CXCR1 CCL11
23 meningitis 31.5 IL10 IFNG CCL3 CCL2
24 disease of mental health 31.4 TLR3 ITIH4 IL10 IFNG CXCL12 CX3CR1
25 chlamydia 31.4 IL10 IFNG CCL2
26 autoimmune disease 31.4 IL10 IFNG CCR5 CCL3 CCL2
27 lung disease 31.4 IL10 IFNG CXCR1 CCR5 CCL3 CCL2
28 rubella 31.4 TLR3 IL4R IL10 IFNG HLA-C
29 mumps 31.4 TLR3 IL4R IL10 IFNG
30 hepatitis a 31.4 TLR3 IL10 IFNG
31 aseptic meningitis 31.3 IL10 IFNG CCL3
32 tropical spastic paraparesis 31.3 IL10 IFNG CCL3
33 graft-versus-host disease 31.3 IL10 IFNG HLA-C
34 pneumonia 31.3 TLR3 IL10 IFNG CCL3 CCL2 CCL11
35 dengue disease 31.3 IL10 IFNG CD209 CCL3
36 neuritis 31.2 IL10 IFNG CX3CR1 CCR5 CCL3 CCL2
37 severe acute respiratory syndrome 31.2 IL10 IFNG HLA-C CD209 CCL2
38 periodontitis 31.2 IL10 IFNG CCL2
39 poliomyelitis 31.2 TLR3 IL10 IFNG
40 leptospirosis 31.2 IL10 IFNG CCL2
41 otitis media 31.2 IL10 IFNG CCL11
42 multiple sclerosis 31.1 TLR3 IL4R IL10 IFNG CXCL12 CX3CR1
43 proteasome-associated autoinflammatory syndrome 1 31.1 IL10 IFNG CCL3 CCL2 CCL11
44 lymphadenitis 31.1 IL10 IFNG CD209
45 vascular disease 31.1 IL10 IFNG CXCL12 CX3CR1 CCL2
46 sarcoidosis 1 31.1 IFNG CCR5 CCL3 CCL2 CCL11
47 secondary syphilis 31.1 CD209 CCR5
48 malaria 31.0 KIR3DL1 IL4R IL10 IFNG HLA-C CXCL12
49 chagas disease 31.0 IL10 IFNG CCR5 CCL3 CCL2
50 polyradiculoneuropathy 31.0 IL10 IFNG CXCL12

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM®:

609423 (Updated 05-Mar-2021)

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

GenomeRNAi Phenotypes related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10 CCL2
2 Decreased viability GR00221-A-4 10 CCL2 CCR2
3 Decreased viability GR00240-S-1 10 BST2
4 Decreased viability GR00249-S 10 CD9 CX3CR1 IL4R TLR3
5 Decreased viability GR00342-S-1 10 TLR3
6 Decreased viability GR00342-S-2 10 TLR3
7 Decreased viability GR00381-A-1 10 CX3CR1 CXCR1
8 Decreased viability GR00381-A-3 10 CX3CR1
9 Decreased viability GR00386-A-1 10 CCL2 CCL3 CCL3L1 CXCR1 ITIH4
10 Decreased viability GR00402-S-2 10 CCL2 CCNT1 CX3CR1 TLR3
11 Increased the percentage of infected cells GR00402-S-1 8.62 IL10 TLR3

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCL11 CCR2 CCR5 CD209 CD9 CX3CR1
2 immune system MP:0005387 9.9 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 neoplasm MP:0002006 9.5 CCR2 CCR5 CD9 IFNG IL10 ITIH4
4 respiratory system MP:0005388 9.23 CCL11 CCR2 CCR5 CD9 IFNG IL10

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 896)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
2
Glycerol Approved, Investigational Phase 4 56-81-5 753
3
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
4
Misoprostol Approved Phase 4 59122-46-2 5282381
5
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Lopinavir Approved Phase 4 192725-17-0 92727
8
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
9
Zidovudine Approved Phase 4 30516-87-1 35370
10
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
11
Fosamprenavir Approved Phase 4 226700-79-4 131536
12
Indinavir Approved Phase 4 150378-17-9 5362440
13
Didanosine Approved Phase 4 69655-05-6 50599
14
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
15
Acyclovir Approved Phase 4 59277-89-3 2022
16
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
17
Ethambutol Approved Phase 4 74-55-5 3279 14052
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Lactitol Approved, Investigational Phase 4 585-86-4 157355
20
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
22
Losartan Approved Phase 4 114798-26-4 3961
23
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
24
Sorbitol Approved Phase 4 50-70-4 5780
25
Atovaquone Approved Phase 4 95233-18-4 74989
26
Proguanil Approved Phase 4 500-92-5 4923
27
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
28
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
29
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
30
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
31
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
32
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
33
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
34
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
35
Travoprost Approved Phase 4 157283-68-6 5282226
36
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
37
Racepinephrine Approved Phase 4 329-65-7 838
38
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
39
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
40
Desipramine Approved, Investigational Phase 4 50-47-5 2995
41
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
42
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
43
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
44
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
45
Calcium carbonate Approved, Investigational Phase 4 471-34-1
46
Acetaminophen Approved Phase 4 103-90-2 1983
47
Ibuprofen Approved Phase 4 15687-27-1 3672
48
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
49
Citalopram Approved Phase 4 59729-33-8 2771
50
Norepinephrine Approved Phase 4 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 5199)
# Name Status NCT ID Phase Drugs
1 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
2 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
3 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
4 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
5 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
6 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
7 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults Unknown status NCT01017172 Phase 4
8 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
9 HIV Pre-Exposure Prophylaxis Priming of Immune Effectors Unknown status NCT02593409 Phase 4 TDF/FTC
10 A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
11 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
12 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
13 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
14 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
15 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
16 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
17 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
18 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
19 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
20 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
21 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
22 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
23 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
24 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
25 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
26 A Single Site, Three Arm, Open Label Comparative Preference Study to Evaluate the Preference of Consumers and Health Care Professionals for the Use of Shapes by PolyMem Wound Dressings and Shapes by PolyMem Silver Wound Dressings, Each Compared to Antibiotic Ointment Covered With a Band-aid Type Dressing (Current Standard of Practice) and to Each Other in the Post-biopsy Management of Shave Biopsies. Each Participant Serves as Own Control. A Blinded Third Party Physician Will Evaluate and Compare the Wounds Based on Photos Taken at the Various Follow-up Points.. Unknown status NCT00727870 Phase 4
27 A Study on the Fit and Behaviour of Computer-aided Design and Rapid Prototyping Fabrication of Removable Partial Dentures Unknown status NCT01191073 Phase 4
28 Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Unknown status NCT02951559 Phase 4
29 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
30 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
31 Use of Misoprostol by Families and Women as a First Aid Measure to Address Excessive Postpartum Bleeding in Home Deliveries Unknown status NCT02853552 Phase 4 Misoprostol
32 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
33 A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients Completed NCT00127972 Phase 4 stavudine;lamivudine;nevirapine;efavirenz;trizivir
34 A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen. Completed NCT00389402 Phase 4 saquinavir/ritonavir;atazanavir/ritonavir
35 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
36 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
37 Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial Completed NCT02431975 Phase 4 Nevirapine;Zidovudine;Lamivudine;LPV/r
38 Optimization of Darunavir Therapy Through Population Pharmacokinetic Modeling, Simulations and Dosage Guidelines Completed NCT03101644 Phase 4 Darunavir
39 Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection Completed NCT01121809 Phase 4 Raltegravir;Etravirine
40 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
41 "Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection." Completed NCT03502005 Phase 4 bictegravir/emtricitabine/tenofovir alafenamide
42 Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
43 A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks Completed NCT00082394 Phase 4 Trizivir;atazanavir;Combivir
44 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etravirine (ETR) in Combination With Other Antiretrovirals (ARVs) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Completed NCT01422330 Phase 4 Etravirine
45 Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects Completed NCT00549198 Phase 4 Abacavir/lamivudine and efavirenz;Tenofovir/Emtricitabine and efavirenz
46 A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects Completed NCT01102972 Phase 4 Reyataz + Norvir + Truvada;Reyataz + Epzicom
47 PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment Completed NCT02167386 Phase 4
48 Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults Completed NCT01025830 Phase 4 Triomune;Zerit/Epivir/Viramune
49 Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients Completed NCT00810108 Phase 4 lopinavir/ritonavir (Kaletra®) tablets
50 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence Completed NCT03218592 Phase 4 Maraviroc Pill;Dolutegravir Pill;Truvada Pill

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 71 / NDF-RT 51 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3

Anatomical Context for Human Immunodeficiency Virus Type 1

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

40
T Cells, Bone, Brain, Prostate, Breast, Monocytes, Endothelial

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 50017)
# Title Authors PMID Year
1
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 57 54 61 6
12134147 2002
2
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) 61 54 57 6
9430590 1998
3
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. 61 54 6 57
9252328 1997
4
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. 61 6 57
19935663 2009
5
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 61 57 6
15564514 2004
6
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. 61 6 57
11121048 2000
7
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. 57 6
22174453 2012
8
MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. 6 57
14571188 2003
9
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 6 57
8756719 1996
10
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 57 6
8751444 1996
11
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. 61 54 57
17243065 2007
12
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. 57 54 61
16189667 2005
13
Genetic acceleration of AIDS progression by a promoter variant of CCR5. 57 54 61
9836644 1998
14
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). 61 6 54
9742978 1998
15
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 54 57 61
8791590 1996
16
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. 57 61
22190037 2011
17
The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. 61 57
20871604 2010
18
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. 57 61
18806803 2008
19
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. 57 61
18621010 2008
20
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. 61 57
17906637 2007
21
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. 61 57
17570119 2007
22
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. 57 54
17360650 2007
23
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. 61 57
17306567 2007
24
Structural definition of a conserved neutralization epitope on HIV-1 gp120. 57 61
17301785 2007
25
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. 61 57
16288280 2005
26
The case for selection at CCR5-Delta32. 54 6
16248677 2005
27
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. 61 57
15637236 2005
28
Influence of host genetic variation on susceptibility to HIV type 1 infection. 61 57
15630678 2005
29
Human genes that limit AIDS. 61 57
15167933 2004
30
Modulating influence on HIV/AIDS by interacting RANTES gene variants. 61 57
12114533 2002
31
Chemokine receptor polymorphism in transplantation immunology: no longer just important in AIDS. 6 61
11403804 2001
32
A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression. 54 6
11369664 2001
33
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. 57 61
11386265 2001
34
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 61 57
10073943 1999
35
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 54 6
9600249 1998
36
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 6 54
9132277 1997
37
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. 57
29302013 2018
38
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. 57
26416734 2015
39
SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. 57
26416733 2015
40
HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1. 57
25855743 2015
41
TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability. 57
26056259 2015
42
PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. 57
26046437 2015
43
Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. 57
22988032 2012
44
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. 57
22190036 2011
45
Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. 6
21911422 2011
46
Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection. 57
20843824 2010
47
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. 57
20445539 2010
48
Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. 57
20173753 2010
49
The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. 57
19620399 2009
50
Shared and distinct genetic variants in type 1 diabetes and celiac disease. 6
19073967 2008